Biotech Scan
Biotech Scan
Biotech in capitulation mode — life science tools (DHR, TMO, A, MDT) deeply oversold RSI 23-27, NVO death-spiraling at RSI 33 and -53% from highs, while MRNA rips +86% in 3M and PTGX hits new highs.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 BIFURCATED / RISK-OFF — Life science tools in deep selloff, gene editing fragile, only select pharma holding |
| Leaders | PTGX ($95.23, RSI 62), VRTX ($485.55, RSI 54), MRNA ($54.51, RSI 60) — Working |
| Laggards | MDT ($87.82, RSI 23), DHR ($187.98, RSI 24), TMO ($476.70, RSI 28) — Capitulation zone |
Price Table (2026-03-12)
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | Trend | Signal |
|---|---|---|---|---|---|---|---|
| MDT | $87.82 | 23 ↓ | -8.0% | -4.1% | -13.0% | down | 🟢 Extreme Oversold |
| DHR | $187.98 | 24 ↓ | -8.3% | -3.9% | -12.5% | down | 🟢 Extreme Oversold |
| A | $111.94 | 27 ↓ | -7.4% | -3.2% | -10.4% | down | 🟢 Extreme Oversold |
| TMO | $476.70 | 28 ↓ | -6.3% | -3.3% | -6.5% | down | 🟢 Extreme Oversold |
| HD (defensive ref) | — | — | — | — | — | — | — |
| NVO | $38.11 | 33 ↓ | -8.2% | +0.3% | -22.1% | strong-down | 🔴 Falling Knife |
| BNTX | $88.80 | 33 ↓ | -14.5% | -10.7% | -16.0% | down | 🔴 Breakdown |
| IONS | $72.57 | 32 ↓ | -8.9% | -1.2% | -11.3% | weak-down | 🟡 Approaching Oversold |
| INCY | $92.05 | 32 ↓ | -7.1% | -3.8% | -8.6% | weak-down | 🟡 Approaching Oversold |
| ALNY | $312.14 | 36 ↓ | -4.1% | -0.6% | +1.2% | strong-down | 🟡 Weak |
| ILMN | $118.15 | 37 ↓ | -4.1% | -7.3% | +3.2% | weak-down | 🟡 Weak |
| ISRG | $478.70 | 38 ↓ | -3.3% | 0.0% | 0.0% | down | 🟡 Weak |
| CRSP | $48.87 | 39 ↓ | -11.8% | -13.9% | -0.1% | strong-down | 🟡 Weak |
| LLY | $976.59 | 41 ↓ | -4.1% | +1.5% | -5.8% | weak-down | 🟡 Watch |
| RARE | $21.52 | 41 | -2.8% | +3.0% | -8.4% | strong-down | 🟡 Watch |
| BEAM | $25.74 | 43 | -7.1% | -2.3% | -4.4% | weak-down | 🟡 Watch |
| SRPT | $17.05 | 43 | -2.6% | +6.1% | -2.0% | strong-down | 🔴 Broken |
| XBI | $122.85 | 44 ↓ | -2.3% | +1.7% | -0.3% | weak-down | 🟡 ETF Neutral |
| IBB | $167.17 | 40 ↓ | -3.2% | +0.7% | -2.0% | weak-down | 🟡 ETF Neutral |
| IBBQ | $28.64 | 41 ↓ | -3.1% | +0.9% | -1.7% | weak-down | 🟡 ETF Neutral |
| LABU | $153.24 | 42 ↓ | -7.8% | +4.8% | -2.7% | weak-down | 🟡 3x ETF |
| BMRN | $59.89 | 49 | -1.9% | +0.5% | -0.1% | strong-up | 🟡 Hold |
| NTLA | $12.90 | 49 | -2.6% | -5.4% | +11.0% | strong-up | 🟡 Hold |
| ABBV | $226.80 | 49 | -1.1% | -1.7% | -0.3% | strong-up | 🟡 Hold |
| BIIB | $186.62 | 49 | -2.2% | +0.6% | -4.5% | strong-up | 🟡 Hold |
| REGN | $753.62 | 51 | -3.4% | +0.8% | -3.7% | weak-down | 🟡 Hold |
| AMGN | $370.74 | 51 | -1.5% | +2.1% | +1.9% | strong-up | 🟡 Hold |
| GILD | $146.60 | 52 | -1.5% | +0.7% | -3.4% | strong-up | 🟡 Hold |
| LEGN | $19.42 | 54 | +3.5% | +15.6% | +7.5% | strong-down | 🟡 Bounce |
| EXAS | $103.33 | 54 | 0.0% | 0.0% | +0.1% | strong-up | 🟡 Hold |
| VRTX | $485.55 | 54 | +1.4% | +5.2% | +4.4% | strong-up | 🔒 Hold |
| MRNA | $54.51 | 60 | +7.1% | -2.0% | +35.9% | strong-up | ⚠️ Extended |
| PTGX | $95.23 | 62 | +6.7% | +5.6% | +16.2% | strong-up | 🔒 Hold/Watch |
| EDIT | $2.51 | 62 | +21.2% | +31.0% | +49.4% | weak-up | ⚠️ Chasing |
| DNA | $6.44 | 37 | -18.7% | -3.7% | -26.7% | strong-down | ❌ Avoid |
| RXRX | $3.30 | 36 | -6.9% | -5.8% | -7.8% | strong-down | ❌ Avoid |
| IQV | $165.12 | 36 | -3.2% | -4.8% | -2.2% | down | 🟡 Watch |
| DXCM | $66.43 | 35 | -6.4% | -6.8% | +2.1% | strong-down | 🟡 Watch |
Tier Analysis
EXTREME OVERSOLD (RSI < 30) — Capitulation Territory
MDT (RSI 23), DHR (RSI 24), A (RSI 27), TMO (RSI 28): All life science tools/instruments. This sub-sector is getting wiped — likely a combination of tariff exposure, NIH/FDA budget fears, and macro-driven de-risking. Classic cluster capitulation. These are quality compounders at panic prices IF the thesis holds.
NVO (RSI 33): Not technically extreme but down -53% from 52wk high, death cross confirmed. GLP-1 competitive fears overwhelming. Structural — not a quick bounce candidate.
OVERSOLD (RSI 30-40) — Potential Entries
IONS (RSI 32), INCY (RSI 32): Fundamentally sound RNA/small-molecule players pulling back without thesis breaks. Entry zones approaching.
BNTX (RSI 33): Another gap-down after continued post-COVID disappointment. -32% from 52wk high.
ALNY (RSI 36): RNAi pioneer, -35% from high. Death cross. Long-term thesis intact but near-term pain.
CRSP (RSI 39): Gene editing leader hit hard — -14% in 7 days. -38% from 52wk high. High risk/reward.
NEUTRAL/TRENDING (RSI 40-55) — Hold Zone
Bulk of large-cap biotech (ABBV, AMGN, GILD, BIIB, REGN) clustered RSI 49-52 — mostly holding structure, slight pullbacks off highs. ETFs (XBI, IBB, IBBQ) all RSI 40-44 and slightly below SMA20 — neutral read on sector.
LLY (RSI 41): Pulling back but still golden cross, +10.5% above SMA200. GLP-1 secular story intact.
OVERBOUGHT / LEADERS (RSI > 55)
MRNA (RSI 60, +86% in 3M): Massive reversal from the lows — likely driven by AI drug discovery thesis or pipeline news. Getting extended; watch for pullback to SMA20 (~$50.90) for re-entry.
PTGX (RSI 62, +16% in 30D): Protagonist Therapeutics — near 52wk high, +34% above SMA200. Strong institutional momentum play.
EDIT (RSI 62, +49% in 30D): Gene editing speculative squeeze. +21% above SMA20. Not a buy here.
Entry Zones
| Stock | Current | Zone | RSI | 30D Chg | Action | Notes |
|---|---|---|---|---|---|---|
| MDT | $87.82 | <$92 | 23 ↓ | -13.0% | ✅ Strong Buy | Medical devices leader, deeply oversold, golden cross intact |
| DHR | $187.98 | <$195 | 24 ↓ | -12.5% | ✅ Strong Buy | Life science instruments, quality compounder at deep discount |
| A | $111.94 | <$115 | 27 ↓ | -10.4% | ✅ Strong Buy | Agilent, lab instruments, -28% from 52wk high |
| TMO | $476.70 | <$490 | 28 ↓ | -6.5% | 📈 Accumulate | Thermo Fisher, world-class compounder, -26% from high |
| IONS | $72.57 | <$75 | 32 ↓ | -11.3% | 📈 Accumulate | RNA therapeutics leader, strong 1Y momentum |
| INCY | $92.05 | <$95 | 32 ↓ | -8.6% | 📈 Accumulate | Profitability rare in biotech; JAK inhibitor franchise |
| LLY | $976.59 | <$990 | 41 | -5.8% | 🔍 Watch | GLP-1 king, RSI cooling, watch for RSI < 35 |
| CRSP | $48.87 | <$50 | 39 ↓ | -0.1% | 🔍 Research | Gene editing leader, death cross is caution flag |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| ✅ STRONG BUY | MDT, DHR, A | RSI 23-27, quality companies in cluster capitulation |
| 📈 ACCUMULATE | TMO, IONS, INCY | Oversold 28-32, thesis intact, DCA opportunity |
| 🔒 HOLD | PTGX, VRTX, ABBV, AMGN, GILD | Core positions, trends intact |
| 🔍 WATCH | LLY, CRSP, ALNY, IQV | Pulling back, need more confirmation |
| ⚠️ AVOID / DON'T CHASE | MRNA, EDIT | Parabolic 30D moves, overbought |
| ❌ DON'T BUY | NVO, DNA, RXRX, SRPT | Structural downtrends, falling knives |
What Changed
- Life science tools capitulating (DHR, TMO, A, MDT): This is the standout theme — a cluster of quality names getting sold with RSI 23-28. Likely macro + NIH/government funding fears. Buy zone for long-term holders.
- NVO continues free-fall: -22% in 30D, -53% from high. GLP-1 thesis eroding as competition intensifies. No entry signal yet.
- MRNA reversal (+86% in 3M): From deep lows to near 52wk high. Likely AI drug discovery / pipeline catalyst. Do not chase.
- PTGX new high territory: Small-cap biotech breaking out while sector bleeds — watch for continued strength.
- BNTX breakdown: -10.7% in 7D, -32% from 52wk high. Post-COVID secular decline continues.
- Biotech ETFs (XBI, IBB) holding relative to individual names — sector not in panic, more of a rotation away from small-mid growth names.
Key Discoveries
| Discovery | Implication |
|---|---|
| Life science tools (DHR/TMO/A/MDT) all RSI 23-28 simultaneously | Cluster capitulation — potential sector rotation buy, not stock-specific issues |
| MRNA +86% in 3M while sector sells off | AI drug discovery narrative creating divergence within biotech |
| NVO death cross + -53% from high | GLP-1 competitive moat questions are serious — no buy signal |
Open Questions
Related
10 eventsNo direct external sources are attached to this read.